(HealthDay News) — Liraglutide (Victoza®, Novo Nordisk) does not appear to improve heart function in patients with advanced heart failure, according to a study published in the Journal of the American Medical Association.
Kenneth Margulies, MD, a professor of medicine and research director of heart failure and transplantation at the University of Pennsylvania in Philadelphia, and colleagues randomly assigned 300 recently hospitalized advanced heart failure patients to daily injections of liraglutide or placebo. Over 6 months, the researchers looked for the number of patients who died, who were readmitted to the hospital for heart failure, or whose disease had stabilized.
Among the 271 patients who completed the study, liraglutide had no significant effect on any of the outcomes Dr Margulies’ team was looking for. Among those taking liraglutide, 12% died vs 11% of those receiving placebo. Forty-one percent of those taking liraglutide were rehospitalized for heart failure, compared with 34% of those receiving placebo.
No difference was seen between the groups in measurements of heart function and disease stability, including heart structure and function, 6-minute walking distance, and quality of life. And, when the researchers looked at those with and without diabetes, they did not see any significant differences between the groups.
“Among patients recently hospitalized with heart failure and reduced left ventricular ejection fraction, the use of liraglutide did not lead to greater posthospitalization clinical stability,” the researchers wrote. “These findings do not support the use of liraglutide in this clinical situation.”
Margulies KB, Hernandez AF, Redfield MM, et al; for the NHLBI Heart Failure Clinical Research Network. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.JAMA. 2016;316(5):500-508. doi:10.1001/jama.2016.10260.